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Imaging genetics approach 
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Mansu Kim1,2, Jonghoon Kim1,2, Seung-Hak Lee1,2 & Hyunjin Park2,3
Parkinson’s disease (PD) is a progressive neurodegenerative disorder associated with both underlying 
genetic factors and neuroimaging findings. Existing neuroimaging studies related to the genome in 
PD have mostly focused on certain candidate genes. The aim of our study was to construct a linear 
regression model using both genetic and neuroimaging features to better predict clinical scores 
compared to conventional approaches. We obtained neuroimaging and DNA genotyping data from 
a research database. Connectivity analysis was applied to identify neuroimaging features that could 
differentiate between healthy control (HC) and PD groups. A joint analysis of genetic and imaging 
information known as imaging genetics was applied to investigate genetic variants. We then 
compared the utility of combining different genetic variants and neuroimaging features for predicting 
the Movement Disorder Society-sponsored unified Parkinson’s disease rating scale (MDS-UPDRS) 
in a regression framework. The associative cortex, motor cortex, thalamus, and pallidum showed 
significantly different connectivity between the HC and PD groups. Imaging genetics analysis identified 
PARK2, PARK7, HtrA2, GIGYRF2, and SNCA as genetic variants that are significantly associated with 
imaging phenotypes. A linear regression model combining genetic and neuroimaging features predicted 
the MDS-UPDRS with lower error and higher correlation with the actual MDS-UPDRS compared to 
other models using only genetic or neuroimaging information alone.
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by bradykinesia, resting trem-
ors, rigidity, and difficulty with voluntary movement1. Typically, PD is diagnosed using criteria such as the United 
Kingdom’s Parkinson’s Disease Society Brain Bank2. The pathological hallmark of PD is the loss of dopaminergic 
neurons in the substantia nigra (SN) and those that project into the striatum. This neuronal loss leads to dopa-
mine imbalance, which may result in inhibition of basal ganglia output and dysfunction within the cortico-basal 
ganglia-thalamocortical (CBGT) circuit3,4. Environmental toxins and genetic factors have been linked to the 
development of PD5. More than 16 PD-related genetic mutations have been recognized6.
Various neuroimaging approaches have been used to investigate how PD affects the brain4,7–10. These imag-
ing approaches include positron emission tomography (PET), single-photon emission computed tomogra-
phy (SPECT), and magnetic resonance imaging (MRI). Functional dopaminergic imaging such as dopamine 
transporter SPECT has been widely used to assess nigrostriatal degeneration11. White matter integrity could be 
assessed using diffusion MRI and tractography, which allows investigation of neuronal degeneration12. These 
various neuroimaging approaches allow us to better understand the neurobiological mechanism of PD13.
Existing neuroimaging studies related to the genome of PD have focused on certain candidate genes14,15. 
Recently, genome-wide association study (GWAS) has been used to identify genetic polymorphisms that influ-
ence disease phenotypes16. Common genetic variants that are associated with many diseases such as Alzheimer’s 
disease, PD, and diabetes have been successfully identified using GWAS16,17. Genes associated with PD have been 
identified using GWAS6,18. GWAS is frequently limited by the need for a large number of data samples to achieve 
statistical significance. Sample size requirements can be reduced using quantitative trait analysis, a form of genetic 
analysis that uses intermediate phenotypes of the disorder being studied19. Imaging genetics is a type of quantita-
tive trait analysis that uses imaging measures (e.g., functional connectivity and brain activation) that are heritable 
and correlated with the disease in question.
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Imaging genetics is an emerging tool that is capable of identifying the genetic risk of a disease based on 
both clinical factors and imaging techniques20. Imaging techniques provide complementary high dimensional 
information regarding the disease, and thus, GWAS could be improved by such additional information. Existing 
imaging genetic studies have been applied to Alzheimer’s disease and schizophrenia17,19,21–23. However, the appli-
cation of imaging genetics for PD has been scarce. Prior imaging genetics studies have focused on specific gene 
candidates and have not used imaging measures for quantitative trait analysis14,15. One study investigating the 
cause of familial PD using functional PET imaging and genetic data reported that a mutation in the LRRK2 gene 
led to familial PD14. Another study investigated the early progression of PD in patients with mutant Parkin and 
PINK genes using functional MRI (fMRI)15. They showed that Parkin mutation carriers had abnormalities in the 
supplementary motor area and premotor cortex during a simple sequence task and that PINK mutation carriers 
were affected in the same regions during a finger sequence task.
In our study, we applied imaging genetics combining genetic polymorphisms and brain connectivity measure-
ments as intermediate phenotypes to identify clinically relevant genetic variants in PD. Another aim of our study 
was to determine if the use of genetic variants along with their associated neuroimaging features could better pre-
dict clinical scores of PD progression compared to using conventional approaches with GWAS or neuroimaging 
alone. We obtained diffusion MRI and DNA genotyping data from the Parkinson’s disease Progression Marker 
Initiative (PPMI) database24. Connectivity analysis was used to identify neuroimaging features within the CBCT 
circuit that could differentiate between healthy control (HC) and PD groups. These neuroimaging features and 
associated clinical scores were used as intermediate phenotypes in imaging genetics analysis to identify clinically 
relevant genetic variants. We then analyzed the utility of combining different genetic variants and neuroimag-
ing features for predicting the Movement Disorder Society-sponsored unified Parkinson’s disease rating scale 
(MDS-UPDRS), a well-established measure reflecting motor symptoms and clinimetric properties of PD, using 
a regression framework25.
Results
Subject selection. First, quality control of genotype data was performed based on the Enhancing Neuro 
Imaging Genetics through Meta Analysis (ENIGMA) protocol. In total, single-nucleotide polymorphisms 
(SNPs) with a minor allele frequency < 1% (n = 53,482), Hardy-Weinberg equilibrium < 10−6 (n = 683), and a 
genotype missing rate > 5% (n = 14,378) were excluded from the study. Following quality control, 136,350 SNPs 
remained for further analysis. Second, the population stratification of the genetic data was adjusted using mul-
tidimensional scaling. After population stratification, only unrelated Caucasian subjects (n = 418) remained 
(Supplementary Figure S1). Of these unrelated Caucasian subjects, 146 (HC = 40, PD = 106) had both neuroim-
aging and genetic data available in the database. Forty of these PD cases were then randomly chosen to achieve 
equal numbers of samples in each group.
Connectivity differences. Differences between the HC and PD groups were quantified in terms of degree 
centrality (DC) values using t-tests with Bonferroni correction. Four regions, namely the associative cortex, motor 
cortex, thalamus, and pallidum, had significantly different DC values between the HC and PD groups (Table 1). 
The associative cortex, motor cortex, and thalamus showed increased DC values in PD patients compared with 
HC subjects, while the pallidum showed reduced DC values in PD patients compared with HC subjects.
Genetic variants in imaging genetics analysis. The results of imaging genetics analysis using the DC 
values of the associative cortex, motor cortex, thalamus, and pallidum and MDS-UPDRS are shown in Table 2. 
Three SNPs were associated with the DC values of these four regions, and four SNPs were associated with the 
MDS-UPDRS. PARK2 (which contained three SNPs) was associated with the DC value of the associative cortex 
and MDS-UPDRS. PARK7 was associated with the DC value of the motor cortex, and SNCA was associated with 
the DC value of the thalamus. HtrA2 and GIGYF2 were associated with the MDS-UPDRS.
Linear model analysis. We compared three multiple linear regression models to determine which model 
best explained the MDS-UPDRS. Stepwise regression was applied to construct three linear regression models, and 
the process led to different regression models depending on the initial model. Model C (the one with both genetic 
variants and neuroimaging features) (3) showed the best performance (adjusted R-squared (adj-R2) = 0.714, 
p < 0.001) compared to model A (the one with neuroimaging features) (1) and model B (the one with genetic var-
iants) (2), which yielded adj-R2 values of 0.508 (p < 0.001) and 0.442 (p < 0.001), respectively (Tables 3,4 and 5). 
Details regarding the three equations are found in the Methods section. Specifically, the DC value of the pal-
lidum singly explained the greatest (9.70%) variance (F = 21.52, p < 0.001) in model C (3). Model C (3) explained 




Associative cortex 0.017 ± 0.004 0.019 ± 0.004 0.047
Motor cortex 0.012 ± 0.003 0.015 ± 0.003 0.022
Thalamus 0.007 ± 0.002 0.008 ± 0.002 < 0.001
Pallidum 0.006 ± 0.001 0.005 ± 0.001 0.007
Table 1.  DC values of regions with significantly different structural connectivity in PD patients versus HC 
subjects. DC values are reported as the mean ± standard deviation (SD). Corrected p-values are reported in the 
right-hand column.
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the variance in the MDS-UPDRS (Tables 3,4 and 5). Thus, combining genetic variants with neuroimaging fea-
tures resulted in an improved adj-R2 value, indicating that they provide complementary information. Each model 
included a distinct set of independent variables (IVs), and thus, the number of included IVs varied from model 
to model. A given variable might appear in two different models, but its contribution in terms of percentage of 
explained variance could be different as there was a distinct set of IVs in each model. For example, the DC of the 
thalamus explained 10.75% of the variance in conjunction with 5 other IVs in model A, while the DC of the same 
region explained 6.87% in conjunction with 9 other IVs in model C.
Prediction of MDS-UPDRS. The model combining genetic and neuroimaging features, model C (3), pre-
dicted the MDS-UPDRS with root mean squared error (RMSE) of 7.82 and showed a high correlation with the 
actual MDS-UPDRS (r = 0.788, p < 0.001) compared with the models using genetic and neuroimaging features 
alone (model A (1) and model B (2)). The first model with only neuroimaging features, model A (1), showed a high 
RMSE of 10.24 and a correlation of 0.616 (p < 0.001). The second model with only genetic variants, model B (2), 
yielded a RMSE of 11.71 and a correlation of 0.475 (p < 0.001). Plots of the actual and predicted MDS-UPDRS 
scores for these three models are given in Fig. 1.
Discussion
Our main finding showed that the linear prediction model combining neuroimaging and genetics could explain 









Associative cortex PARK2 rs6901583 162543210 C 0.015
Motor cortex PARK7 rs225103 8042301 T 0.043
Thalamus SNCA rs1473533 90735702 T 0.049
MDS-UPDRS
PARK2 rs9346876 162032871 C 0.034
PARK2 rs9364608 162034799 G 0.034
HtrA2 rs363611 74759708 T 0.044
GIGYF2 rs7421653 233711471 G 0.048
Table 2.  Genetic variants identified by imaging genetics analysis using neuroimaging features and clinical 
score as intermediate phenotypes.
Sum of squares F-statistic P-value Pct. Exp. (%)
Associative cortex 682.07 8.65 0.004 5.78
Thalamus 1268.30 16.09 < 0.001 10.75
Pallidum 980.81 12.44 < 0.001 8.31
Family history 1023.50 12.98 < 0.001 8.67
GDS 408.72 5.18 0.025 3.46
Age 190.98 2.42 0.124 1.62
Associative × Family 
history 710.76 9.01 0.004 6.02
Thalamus × GDS 609.60 7.73 0.007 5.16
Family history × Age 410.49 5.20 0.025 3.48
Total 53.25
Table 3.  Detailed results of model A equation (1). Pct. Exp.: percentage of explained variance.
Sum of squares F-statistic P-value Pct. Exp. (%)
rs6901583 (PARK2) 83.13 0.83 0.364 0.67
rs1473533 (SNCA) 136.13 1.36 0.247 1.10
rs9346876 (PARK2) 348.26 3.49 0.066 2.81
rs363611 (HtrA2) 703.45 7.04 0.009 5.68
GDS 303.08 3.03 0.085 2.45
Sex 523.84 5.24 0.025 4.23
rs1473533 × rs363611 1303.70 13.05 < 0.001 10.52
rs9346876 × rs363611 1893.50 18.95 < 0.001 15.28
Total 42.74
Table 4.  Detailed results of model B equation (2). Pct. Exp.: percentage of explained variance.
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the predicted and actual MDS-UPDRS. Our connectivity analysis revealed that the associative cortex, motor 
cortex, thalamus, and pallidum had significantly different DC values between the HC and PD groups. Imaging 
genetics analysis identified PARK2, PARK7, HtrA2, GIGYRF2, and SNCA as genetic variants that are significantly 
associated with intermediate phenotypes. These findings illustrate that the identified PD-related genes might 
yield structural connectivity changes that could be recognized using diffusion MRI within the CBGT circuit. The 
linear regression model combining genetic and neuroimaging features predicted the MDS-UPDRS with a lower 
RMSE and higher correlation with the actual MDS-UPDRS compared to the other models using only genetic or 
neuroimaging information alone.
Many recent neuroimaging studies have investigated PD using brain connectivity4,8,10,26,27. Connectivity analy-
sis assumes that the brain is a complex interconnected network, and it is suitable for exploring large-scale circuits 
that include the cortical-thalamic and cerebro-cerebellar circuits28. Connectivity could be assessed using central-
ity measures including betweenness, eigenvector, degree, and page-rank centrality to assess network properties in 
the brain29. Each centrality characterizes the importance of a given node in terms of global or local contribution 
to the network. There is no single centrality measure that works well in all network assessments, and the opti-
mal centrality measure is different depending on the imaging modality and the disease of concern30. DC has a 
straightforward neurobiological interpretation in structural connectivity networks, and thus, we utilized DC in 
this study. Our connectivity analysis revealed that the associative cortex, motor cortex, thalamus, and pallidum 
had significantly different DC values between the HC and PD groups. Some previous studies also showed that 
these regions were important in PD patients based on fMRI, diffusion MRI, and SPECT8,27,31–33.
Conventional genetic analyses have identified genetic variants linked with PD5,18. Imaging genetics combines 
imaging information with genetic information, allowing for identification of additional genetic variants22. Thus, 
the analysis of PD with imaging genetics might identify additional information to better investigate the neuro-
biological mechanisms of PD. In this study, an effect of PARK2 (Parkin) was observed on the DC value of the 
associative cortex and clinical scores. PARK2 plays an important role in presynaptic and postsynaptic neuronal 
processes34. Mutations in the Parkin protein are responsible for disrupting E3 ubiquitin ligase activity in PD35. 
The associative cortex plays a secondary role in processing motor information in the classic model of the CBGT 
motor circuit31. Previous work showed that a mutation of PARK2 was associated with activity in the left lateral 
orbitofrontal cortex, which is part of the associative cortex36. Another study reported that the DC value of the 
dorsolateral prefrontal sub-region of the associative cortex was increased in PD patients compared to HC using 
resting state-fMRI8. These findings suggest that PARK2 may be linked with connectivity in PD patients and in 
turn may affect the MDS-UPDRS. An effect of PARK7 (DJ-1) was observed on DC values in the motor cortex. 
PARK7 is involved in transcriptional regulation and response to oxidative stress37. The motor cortex is a key 
region involved in motor processing, serving as a major input into the basal ganglia1,13. Our findings suggest that 
PARK7 may affect neurons in the motor cortex and in turn may affect PD symptoms. Previous reports showed 
that characteristic PD findings, such as dopaminergic neuronal death in the SN and motor abnormalities, are 
affected by mutations in PARK737. One resting state-fMRI study showed that connectivity between the putamen 
and motor cortex increased in PD patients27. Another study reported that the DC value of the parietal cortex, a 
sub-region of the motor cortex, was increased in PD patients compared with HC subjects8. Moreover, one dif-
fusion MRI study reported that track density in the primary somatosensory cortex was increased in PD patients 
compared with HC subjects32. Thus, the physiologic association of PARK7 with neurons in the motor cortex sug-
gested by our results could be feasible. The interaction term between rs9346876 (PARK2) and rs363611 (HtrA2) 
Sum of squares F-statistic P-value Pct. Exp. (%)
Motor cortex 472.94 10.30 0.002 4.64
Thalamus 699.97 15.24 < 0.001 6.87
Pallidum 988.10 21.52 < 0.001 9.70
rs6901583 (PARK2) 24.39 0.53 0.469 0.24
rs9346876 (PARK2) 649.43 14.14 < 0.001 6.37
rs7421653 (GIGYF2) 135.18 2.94 0.091 1.33
rs363611 (HtrA2) 277.45 6.04 0.017 2.72
GDS 200.06 4.36 0.041 1.96
Sex 436.84 9.51 0.003 4.29
Age 228.45 4.98 0.029 2.24
Thalamus × rs7421653 430.90 9.38 0.003 4.23
Pallidum × rs6901583 246.29 5.36 0.024 2.42
Pallidum × Age 217.02 4.73 0.034 2.13
rs6901583 × rs363611 448.84 9.78 0.003 4.41
rs9346876 × rs7421653 132.27 2.88 0.095 1.30
rs9346876 × rs363611 927.71 20.20 < 0.001 9.11
rs6901583 × GDS 496.61 10.82 0.002 4.87
rs363611 × GDS 375.28 8.17 0.006 3.68
Total 72.51
Table 5.  Detailed results of model C equation (3). Pct. Exp.: percentage of explained variance.
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led to 15.28% and 9.11% of explained variance for models B and C, respectively, in the linear regression analysis. 
This finding is consistent with previous studies reporting that HtrA2 specifically binds to and directly cleaves the 
E3 ubiquitin ligase PARK238,39.
We performed additional analysis with 14 right-sided and 14 left-sided onset cases in the PD group using 
contralateral ROIs, and detailed results are shown in the supplemental material. We observed better results for the 
reduced 28 patient group compared to using the previous 40 patients in terms of adj-R2 values. Model C’s adj-R2 
improved from 0.714 to 0.768, model A’s adj-R2 improved from 0.508 to 0.650, and model B’s adj-R2 improved 
from 0.422 to 0.485. Similar to the main results with 40 patients, model C (adj-R2 = 0.768) outperformed models 
A (adj-R2 = 0.650) and B (adj-R2 = 0.485) implying that combining genetic variants with neuroimaging features 
indeed was the best model. Similar to the main results, for the reduced 28 patients, model C showed the best 
prediction performance with low RMSE (RMSE = 3.35) and a high correlation with the actual MDS-UPDRS 
(r = 0.847, p < 0.001).
Our study was limited by the small number of available samples. This issue was partly mitigated by analyzing 
SNPs and genes previously linked with PD6. Our work focused on known genetic variants, thereby establishing 
a foundation for future research. The neuroimaging data in our study came from nine different clinical sites, 
but all nine sites adopted the same image acquisition protocol using the same MRI scanner model (Siemens 3T 
scanner) to reduce confounding effects. In addition, we added multi-center information as a nuisance co-variate 
to account for multi-center confounding effects. We restricted the connectivity analysis to eight known regions 
within the CBGT circuit, which did not cover the entire brain. We used a single imaging modality (i.e., diffusion 
MRI) to compute intermediate phenotypes of PD. A multi-modal imaging study, potentially including PET and 
SPECT, could provide complementary information and thus has the potential to provide further insight into the 
pathophysiology of PD. Finally, we retrieved data from a research database that lacked follow-up longitudinal 
data. Future work should consider longitudinal data to test the validity of our models.
Figure 1. Plots of actual and predicted MDS-UPDRS for three prediction models. Sub-figures (a,b and c)  
show actual and predicted MDS-UPDRS from Models A (1), B (2), and C (3), respectively. The dashed line 
indicates the identity line (i.e., actual score = predicted score). (d) shows error plots of the three models.
www.nature.com/scientificreports/
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Methods
Subjects and imaging acquisition. This study was a retrospective analysis of anonymized data, and 
institutional review board (IRB) approval was obtained at Sungkyunwkan University. Our study was per-
formed in full accordance with the local IRB guidelines. Informed consent was obtained from all subjects. 
The baseline neuroimaging (T1-, T2-, and diffusion MR) and DNA genotyping data were obtained from the 
PPMI research database24. In detail, diffusion MRI scans were acquired with the following acquisition param-
eters: TR = 900 ms, TE = 88 ms, b = 1000 s/mm2, 64 diffusion gradient directions with one b0 image, image 
matrix = 116 × 116 × 72, and voxel resolution = 1.98 × 1.98 × 2 mm3. T1-weighted MRI scans were acquired 
using the following parameters: TR = 2300 ms, TE = 2.98 ms, TI = 900 ms, image matrix = 240 × 256 × 176, 
and voxel resolution = 1 × 1 × 1 mm3. T2-weighted MRI scans were acquired using the following parameters: 
TR = 3000 ms, TE = 101 ms, image matrix = 228 × 256 × 48, and voxel resolution = 0.9375 × 0.9375 × 3 mm3. 
The PPMI database included 423 PD and 196 HC cases as of July 2015. PD cases were classified using the criteria 
established by the PPMI consortium24. Subjects who underwent both MRI imaging and genetic testing were 
considered for this study. We used off-medication subjects so that the effects of levodopa therapy were excluded. 
Additional patient data including MDS-UPDRS, Hohn and Yahn, Geriatric Depression Scale (GDS), Montreal 
Cognitive Assessment (MoCA), handedness and family history were collected for each case at the baseline visit 
(Supplementary Table S1). Population stratification of genetic data was adjusted using multidimensional scaling. 
We used multidimensional scaling analysis based on the ENIGMA protocol to reduce the population stratifi-
cation and to ensure genetic homogeneity for all subjects40. All quality controlled SNPs were compared to the 
HapMap3 reference population using Plink v1.09 software41. Identity by state distance was calculated for all auto-
somal SNPs so that only unrelated Caucasian subjects remained. Of these unrelated Caucasian subjects, we chose 
40 HC and 40 PD cases as shown in the Results section. The age, sex ratio, handedness, and cognitive assessments 
of the HC and PD groups were matched (Supplementary Table S1). Among 40 PD patients, 14 were right-sided, 
14 were left-sided, and 12 were bilateral onset cases.
Tractography. Diffusion MRI data were processed with tractography, an algorithm that can extract in vivo 
neuronal fiber information, as described in Fig. 2. In brief, distortions due to eddy currents and head motion 
were first corrected using FSL. Second, T1-, T2-, and diffusion-weighted MRI scans were aligned to the Montreal 
Neurological Institute space with non-linear registration using FSL42. Then, white matter, gray matter, and cere-
brospinal fluid were segmented from the registered T1-weighted image using Freesurfer43. The segmented white 
matter was used to guide the tractography algorithm. Fiber information was computed using the determinis-
tic tractography algorithm implemented in the Diffusion Toolkit44. For connectivity analysis (performed with 
MATLAB), structural connectivity matrices were constructed using a deterministic tractography algorithm.
Region of interest specification. Connectivity analysis requires nodes and edges in a graph structure. 
Eight ROIs associated with PD were adopted from the existing literature and used as connectivity nodes4. The 
eight ROIs were the caudate, putamen, pallidum, thalamus, sensorimotor cortex, associative cortex, limbic cortex 
(specified by the Desikan-Killiany atlas) and SN (specified by transferring ROI information from a pre-defined 
atlas via image co-registration) (Fig. 3)45,46. These regions are members of the CBGT circuit and are known to be 
associated with motor, executive, and movement functions1,4,47,48.
Structural connectivity analysis. Structural connectivity was computed using eight regions as nodes and 
the fiber density between two regions as edges. The fiber density between two regions was defined as follows: 
= ∑ ×+ ∈fiber density i j mean FA i j( , ) ( , ),S S f fibers l f
2 1
( )i j
 where f is the fiber connection between regions i and j, 
l(f) is the length of the fiber connection, Si is the surface area of region i, and mean FA(i, j) is the mean fractional 
anisotropy value along all fiber connections between regions i and j. In other words, fiber density was calculated 
as the connection efficiency between two regions, which was further defined as the number of fibers normalized 
by length and surface area49–53. The edge values were entered as elements of the matrix, referred to as the connec-
tivity matrix. A simple network model that considered undirected and weighted edges was used to construct the 
brain network. We adopted DC, which is a simple and sensitive measure of structural connectivity, to measure the 
properties of the brain networks30. DC was computed as the sum of all edge weights connected in a given node54. 
DC represents the importance of a given node, where a high DC value signifies high information flow in the node. 
The microstructure of white matter is under strong genetic control, and thus, the white matter structural connec-
tivity might be affected by genes55.
Group-wise differences in neuroimaging. Group-wise differences in neuroimaging were assessed with 
t-tests and Bonferroni correction between the HC and PD groups. For each group, the DC values of the eight 
nodes were stacked into three-dimensional matrices. Each group had a single three-dimensional matrix. Each 
element in the stacked connectivity matrix contained 40 observations. We performed t-tests to compare between 
the HC and PD groups to assess group-wise differences. Multiple comparison issues were corrected using the 
Bonferroni correction (p < 0.05, corrected)56,57. DC values of regions with significant differences were used as 
intermediate phenotypes for imaging genetics.
Genetic quality control. We quality controlled DNA genotyping data based on the ENIGMA protocol40. 
Quality control of genotype data was performed based on minor allele frequency, genotype missing rate, 
Hardy-Weinberg equilibrium, and genotyping rate. SNPs that did not satisfy the criteria were excluded, and 
subjects with a low genotyping rate were also excluded. In total, SNPs with a minor allele frequency < 1%, 
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Hardy-Weinberg equilibrium < 10−6, and a genotype missing rate > 5% were excluded from the study. Following 
quality control, the remaining SNPs were used for further analysis.
Imaging genetics. Imaging genetics analysis was conducted using intermediate phenotypes to identify 
genetic variants associated with PD. In the first analysis, neuroimaging features (i.e., DC values of regions with 
significant differences between HC and PD) were used as intermediate phenotypes. In the second analysis, the 
clinical score (i.e., MDS-UPDRS) was used as an intermediate phenotype. The genetic variance was described 
with an additive model58. Imaging genetics was performed using Plink software41. A linear regression analysis 
was performed at each SNP using the number of minor alleles as the independent variable and various types of 
intermediate phenotype information as the dependent variable. Age and sex were included as covariates in the 
linear model. Significant genetic variants were determined using a permutation test by performing random group 
assignments 10,000 times23,59. We focused on SNPs that were previously linked with PD.
Construction of multiple linear regression models. We constructed linear models using a stepwise 
approach to explain the clinical score (i.e., MDS-UPDRS) for all subjects (i.e., for both the HC and PD groups). 
Figure 2. Overview of neuroimaging and image genetics processing steps. 
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Multiple linear regression models were constructed using imaging features, genetic features, and two-way inter-
actions between them. The multiple linear regression also considered family history information, MoCA, GDS, 
sex, age, and multi-center information as co-variants to control for confounding effects. Stepwise regression 
was applied to construct the regression models explaining the MDS-UPDRS scores60. An initial model with all 
possible independent variables along with interaction terms among them was constructed. Then, a candidate 
independent variable was removed if the removal of the variable led to a smaller p-value for the overall regres-
sion model. The process of variable removal was repeated until there was no improvement of the p-value of the 
regression model. For instance, the initial model considered DC values of four significant ROIs (from Table 1) 
and numerical SNP values of significant genetic variants (from Table 2) as independent variables. Then, each 
independent variable was tested for possible removal as described above. Subsequently, three linear regression 
models were constructed to explain the MDS-UPDRS score. The first model considered only neuroimaging fea-
tures, the second model considered only genetic variants, and the third model considered both genetic variants 
and neuroimaging features:
α β γ ε= × + × + × +Y IMG COV INTER (1)
α β γ ε= × + × + × +Y SNP COV INTER (2)
α β γ δ ε= × + × + × + × +Y IMG SNP COV INTER , (3)
where Y is the clinical score; IMG is the imaging features; SNP is the genetic features; COV is the co-variants; 
INTER are the two-way interactions of predictors; α , β , γ and δ are estimated coefficients; and ε is a residual error 
term. The quality of multiple linear regression was assessed with adj-R2 values.
Prediction and validation of the model. To validate the models, a leave-one-out cross validation method 
was applied by assigning each case as the test set and the remaining cases as the training set. The process was 
repeated 80 times, each time assigning a different test set. The performance of prediction was assessed with 
Pearson’s correlation coefficients between actual and predicted MDS-UPDRS scores. The RMSE was computed to 
quantify differences between the predicted and actual MDS-UPDRS.
Figure 3. ROI specifications. Eight ROIs associated with PD in the CBGT circuit were defined based on 
MR images. The ROIs include the associative cortex, limbic cortex, sensorimotor cortex, caudate, putamen, 
pallidum, thalamus, and substantia nigra.
www.nature.com/scientificreports/
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